4.95
2 Seventy Bio Inc stock is traded at $4.95, with a volume of 4.06M.
It is up +0.00% in the last 24 hours and up +107.11% over the past month.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
See More
Previous Close:
$4.95
Open:
$4.94
24h Volume:
4.06M
Relative Volume:
4.78
Market Cap:
$255.36M
Revenue:
$44.12M
Net Income/Loss:
$-156.25M
P/E Ratio:
-1.6124
EPS:
-3.07
Net Cash Flow:
$-154.61M
1W Performance:
+77.42%
1M Performance:
+107.11%
6M Performance:
+7.84%
1Y Performance:
+4.65%
2 Seventy Bio Inc Stock (TSVT) Company Profile
Name
2 Seventy Bio Inc
Sector
Industry
Phone
339-499-9300
Address
60 BINNEY STREET, CAMBRIDGE
Compare TSVT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TSVT
2 Seventy Bio Inc
|
4.95 | 255.36M | 44.12M | -156.25M | -154.61M | -3.07 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-06-24 | Downgrade | Goldman | Neutral → Sell |
Jan-31-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Jan-31-24 | Downgrade | TD Cowen | Outperform → Market Perform |
Oct-30-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
Oct-12-23 | Initiated | Citigroup | Buy |
Sep-13-23 | Downgrade | Goldman | Buy → Neutral |
Sep-12-23 | Downgrade | Guggenheim | Buy → Neutral |
Jul-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-31-22 | Initiated | Guggenheim | Buy |
May-02-22 | Initiated | Goldman | Buy |
Feb-10-22 | Initiated | SVB Leerink | Outperform |
Jan-06-22 | Initiated | Cowen | Outperform |
Nov-09-21 | Initiated | Canaccord Genuity | Buy |
Nov-08-21 | Initiated | Morgan Stanley | Overweight |
Nov-08-21 | Initiated | Wedbush | Outperform |
View All
2 Seventy Bio Inc Stock (TSVT) Latest News
2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World
Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report - Simply Wall St
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress - Business Wire
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results - GlobeNewswire
2 Seventy Bio Inc Stock (TSVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2 Seventy Bio Inc Stock (TSVT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Snow Jessica | See Remarks |
Jan 03 '25 |
Sale |
2.94 |
1,000 |
2,936 |
152,479 |
Snow Jessica | See Remarks |
Jan 07 '25 |
Sale |
2.64 |
186 |
491 |
147,179 |
Leschly Nick | Director |
Jan 03 '25 |
Sale |
2.94 |
85,978 |
252,423 |
1,234,498 |
Leschly Nick | Director |
Jan 06 '25 |
Sale |
2.78 |
892 |
2,478 |
1,233,606 |
Eatwell Victoria | Chief Financial Officer |
Jan 03 '25 |
Sale |
2.94 |
1,013 |
2,974 |
339,076 |
Eatwell Victoria | Chief Financial Officer |
Jan 06 '25 |
Sale |
2.78 |
97 |
270 |
338,979 |
Baird William D III | President and CEO |
Jan 03 '25 |
Sale |
2.94 |
31,718 |
93,121 |
862,889 |
Baird William D III | President and CEO |
Jan 06 '25 |
Sale |
2.78 |
763 |
2,120 |
862,126 |
Snow Jessica | See Remarks |
Dec 13 '24 |
Sale |
3.23 |
2,287 |
7,393 |
153,479 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):